In eosinophilic individuals , benralizumab reduced exacerbation rates compared with placebo in the 100 mg group ( 034 vs 057 , reduction 41 % , 80 % CI 11 to 60 , p = 0096 ) but not in the 2 mg group ( 065 vs 057 , difference -9 % , 80 % CI -59 to 26 , p = 0781 ) or the 20 mg group ( 037 vs 057 , reduction 36 % , 80 % CI 3 to 58 , p = 0173 ) .